The estimated Net Worth of Nicholas Simon is at least $267 Thousand dollars as of 28 September 2018. Mr. Simon owns over 333,333 units of Sientra Inc stock worth over $56,667 and over the last 16 years he sold SIEN stock worth over $0. In addition, he makes $210,000 as Lead Independent Director at Sientra Inc.
Nicholas has made over 1 trades of the Sientra Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 333,333 units of SIEN stock worth $4,999,995 on 28 September 2018.
The largest trade he's ever made was buying 333,333 units of Sientra Inc stock on 28 September 2018 worth over $4,999,995. On average, Nicholas trades about 19,608 units every 0 days since 2008. As of 28 September 2018 he still owns at least 333,333 units of Sientra Inc stock.
You can see the complete history of Mr. Simon stock trades at the bottom of the page.
Nicholas J. Simon III serves as Lead Independent Director of the Company. He has served as a director of the Company since April 2007 and as the lead independent director since November 2015. He served as the Chairman of our Board from March 2012 until November 2015. Mr. Simon has been a Senior Managing Director of Blackstone Life Sciences since December 2018 when Blackstone acquired Clarus, a venture capital firm focused on life sciences companies, which Mr. Simon was the co-founder and Managing Director since the firm’s inception in 2005. Prior to Clarus, Mr. Simon was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 25 years of operating and investment experience in the biopharmaceutical industry including Genentech from 1989 to 2000 where he was Vice President of Business and Corporate Development. Mr. Simon is currently a member of the board of directors of Gritstone Oncology, Lycera, and Nuvelution Pharma. He has also been a member of the board of directors of numerous private and public life sciences companies including Achillion, Avanir Pharmaceuticals (acquired by Otsuka Pharmaceuticals), Barrier Therapeutics (acquired by Stiefel Laboratories), BioVitrum AB (acquired by AstraZeneca), CoTherix (acquired by Actelion/Johnson and Johnson), QuatRX Pharmaceuticals, Rigel, Rinat (acquired by Pfizer) and Sangstat (acquired by Genzyme). Mr. Simon is also a trustee of the J. David Gladstone Institutes, a private not-for-profit research institute affiliated with the University of California, San Francisco. Mr. Simon received a B.S. in microbiology from the University of Maryland and an MBA from Loyola University.
As the Lead Independent Director of Sientra Inc, the total compensation of Nicholas Simon at Sientra Inc is $210,000. There are 5 executives at Sientra Inc getting paid more, with Jeffrey Nugent having the highest compensation of $3,015,280.
Nicholas Simon is 66, he's been the Lead Independent Director of Sientra Inc since 2015. There are 1 older and 6 younger executives at Sientra Inc. The oldest executive at Sientra Inc is Jeffrey Nugent, 72, who is the Chairman of the Board, Chief Executive Officer.
Nicholas's mailing address filed with the SEC is 420 SOUTH FAIRVIEW AVENUE, SUITE 200, , SANTA BARBARA, CA, 93117.
Over the last 10 years, insiders at Sientra Inc have traded over $15,843,498 worth of Sientra Inc stock and bought 1,651,210 units worth $23,354,020 . The most active insiders traders include Llp Abingworth, Advisors Llc Orbi Med Capit..., and Timothy Haines. On average, Sientra Inc executives and independent directors trade stock every 73 days with the average trade being worth of $17,193. The most recent stock trade was executed by Ronald Menezes on 10 November 2021, trading 78,498 units of SIEN stock currently worth $445,084.
Sientra Inc executives and other stock owners filed with the SEC include: